Synthesis and activity of dermorphin-growth hormone releasing factor hybrid peptides.
Dermorphin- growth hormone releasing factor (GRF) hybrid peptides (Y-Tyr-D-Ala-Xaa-Gly-Tyr-Pro-Ser-NH2) were synthesized and tested for opioid activity and their ability to stimulate growth hormone (GH) secretion. The substitution of Phe3 for Asp and Glu in dermorphin or its N-terminal acetylation produced peptides with no affinity for opioid receptors but significant, even if low, GRF-like activity.
Marastoni
M
M
Department of Pharmaceutical Sciences, University of Ferrara, Italy.
Salvadori
S
S
Balboni
G
G
Borea
P A
PA
Tomatis
R
R
D000818:Animals; D001923:Brain Chemistry / Q000187:drug effects; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D004305:Dose-Response Relationship, Drug; D013006:Growth Hormone / Q000097:blood; D013007:Growth Hormone-Releasing Hormone / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D006168:Guinea Pigs; D066298:In Vitro Techniques; D008297:Male; D009842:Oligopeptides / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D018847:Opioid Peptides; D051381:Rats
D009842:Oligopeptides; D018847:Opioid Peptides; C030058:dermorphin; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone